Helen E. McGrath

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

Charlotte Benson, Jeff White, Johann S. de Bono et al. · British Journal of Cancer · 2006 · 259 citations · Full text

Medicine, Oncology, Pharmacology +14

Lomeguatrib, a Potent Inhibitor of <i>O</i>6-Alkylguanine-DNA-Alkyltransferase: Phase I Safety, Pharmacodynamic, and Pharmacokinetic Trial and Evaluation in Combination with Temozolomide in Patients with Advanced Solid Tumors

Malcolm Ranson, Mark R. Middleton, John Bridgewater et al. · Clinical Cancer Research · 2006 · 143 citations · Full text

Medicine, Oncology, Pharmacology +17

Biologic significance of constitutive and subliminal growth factor production by bone marrow stroma

EL Kittler, Helen E. McGrath, D Temeles et al. · Blood · 1992 · 143 citations · Full text

Life Sciences, Cell Biology, Pathology +10

Recombinant murine granulocyte macrophage colony-stimulating factor has megakaryocyte colony-stimulating activity and augments megakaryocyte colony stimulation by interleukin 3.

B E Robinson, Helen E. McGrath, P. J. Quesenberry · Journal of Clinical Investigation · 1987 · 135 citations · Full text

Life Sciences, Immunology, Microbiology +10

Salt Sensitivity of Blood Pressure Is Associated With Polymorphisms in the Sodium-Bicarbonate Cotransporter

Robert M. Carey, Cynthia D. Schoeffel, John J Gildea et al. · Hypertension · 2012 · 95 citations · Full text

Life Sciences, Genetics, Physiology +13